巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Silk Road Medical

    SILK
    47.250
    0.530
    1.11%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Silk Road Medical - 延遲價格・最後更新於 05/10 3:29
    最高位
    47.420
    最低位
    46.410
    開市價
    --
    前收市價
    47.780
    成交量(千)
    0.92
    成交額(百萬)
    0.41
    買入
    47.090
    賣出
    47.330
    每手股數
    --
    市值(百萬)
    1,665.09
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    63.215 - 27.210
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Silk Road Medical
    證券代碼
    SILK.US
    所屬板塊
    Medical Devices
    公司業務
    Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of innovative endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
    發行量
    35010136
    公司總部
    1213 Innsbruck Drive
    公司網址
    https://www.silkroadmed.com
    公司電郵
    investors@silkroadmed.com
    公司電話
    +1 408 720-9002
    暫無內容

    關於

    Silk Road Medical(SILK.US)所屬的行業板塊為Medical Devices。
    Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of innovative endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
    詳細公司背景可參考: https://www.silkroadmed.com